<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03853642</url>
  </required_header>
  <id_info>
    <org_study_id>UniversitairZB 18-409</org_study_id>
    <nct_id>NCT03853642</nct_id>
  </id_info>
  <brief_title>Blood Eosinophil Measurements in Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Blood Eosinophil Measurements Throughout the Day in Patients With Stable Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vrije Universiteit Brussel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the within-day variation of blood eosinophils in patients with Chronic
      Obstructive Pulmonary disease (COPD) in stable state and determine if there is a correlation
      between the blood eosinophils and certain clinical parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COPD is a heterogeneous disease, resulting in different phenotypes with varying clinical and
      pathophysiological characteristics. One of these pathophysiological features is chronic
      airway inflammation which can be eosinophilic of nature. Blood eosinophils could be an
      accessible biomarker for this eosinophilic inflammation.

      Eosinophil counts can fluctuate due to their short half-life in blood and due to a diurnal
      rhythm. More needs to be known about this diurnal rhythm and the different confounding
      factors and sources of within-subject variability of this biomarker.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">March 28, 2020</completion_date>
  <primary_completion_date type="Actual">March 28, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Within-day within-subject level changes of blood eosinophils</measure>
    <time_frame>12 hours</time_frame>
    <description>Describe the within-day within-subject levels of blood eosinophils and determine the within-day within-subject variability of blood eosinophils</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Single-arm trial</arm_group_label>
    <description>Patient receiving blood sampling, spirometry and Feno</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling, Spirometry, Fraction exhaled Nitric Oxide</description>
    <arm_group_label>Single-arm trial</arm_group_label>
    <other_name>Spirometry and Fraction exhaled Nitric Oxide</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        COPD patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients willing and able to give informed consent for participation in the study.

          -  Age 18 years or older.

          -  Diagnosis of COPD according to GOLD (Global Initiative for Chronic Obstructive Lung
             Disease): post-bronchodilator Tiffeneau index &lt;0.7), in a stable state of the disease.

          -  A smoking history of &gt;10 pack-years

        Exclusion criteria:

          -  Clinical diagnosis of asthma.

          -  Use of systemic corticosteroids (oral, intravenous or infiltration) up to six weeks
             before inclusion.

          -  Pregnancy.

          -  A recent exacerbation of COPD (&lt;4 weeks).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ines Van Rossem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vrije Universiteit Brussel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universiatir Ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03853642/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

